On November 14, 2019 ThermoGenesis Holdings, Inc. (Nasdaq: THMO) formerly known as Cesca Therapeutics Inc., a market leader in automated cell processing tools and services in the cell and gene therapy field, reported it will delay its third quarter ended September 30, 2019 earnings release and subsequent earnings conference call, previously scheduled for today to Tuesday, November 19, 2019 (Press release, Thermogenesis, NOV 14, 2019, View Source [SID1234551327]). A conference call and webcast will follow at 1:30 p.m. PT/ 4:30 p.m. ET. The company will file a Form 12B-25 with the Securities Exchange Commission to extend its filing deadline for five calendar days until Tuesday, November 19, 2019 for its 10-Q third quarter report. As long as the company files the third quarter 10-Q within the five-day grace period, the report is deemed to have been filed timely by the Securities and Exchange Commission. The delay in filing is to allow for additional time to address complex accounting issues, including the completion of a third-party valuation related to the convertible note issued by the company in the quarter ended September 30, 2019.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada). To access a live webcast of the call, please visit: View Source

A replay of the call will be available until December 10 and can be accessed by dialing 1-877-344-7529 (domestic), 1-412-317-0088 (international) or 1-855-669-9658 (Canada) and referencing access code 10136101. The webcast will be available for three months.

On November 14, 2019 Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, reported that Dr. Nick Glover, President and Chief Executive Officer, will present an overview of the company entitled "Building Momentum for Patients with Myelofibrosis" at the Jefferies 2019 London Healthcare Conference in London, United Kingdom (Press release, Sierra Oncology, NOV 14, 2019, View Source [SID1234551326]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation is scheduled for 6:00 p.m. GMT on Wednesday, November 20, 2019. A live audio webcast and archive of the presentation will be accessible through www.sierraoncology.com.

On November 14, 2019 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported that the company will webcast its corporate presentations at three upcoming investor conferences (Press release, Jazz Pharmaceuticals, NOV 14, 2019, View Source [SID1234551325]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies 2019 London Healthcare Conference in London, UK on Thursday, November 21, 2019 at 10:40 a.m. GMT / 5:40 a.m. EST. Daniel Swisher, president and chief operating officer, will provide an overview of the company and a business and financial update.
Piper Jaffray 31st Annual Healthcare Conference in New York, NY on Tuesday, December 3, 2019 at 8:00 a.m. EST / 1:00 p.m. GMT. Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update.
Evercore ISI 2nd Annual HealthCONx Conference in Boston, MA on Wednesday, December 4, 2019 at 8:00 a.m. EST / 1:00 p.m. GMT. Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update.
A live audio webcast of each presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of each presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

An archive of each webcast will be available for at least one week following each presentation on the Investors section of the company’s website at www.jazzpharmaceuticals.com.

On November 14, 2019 Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, reported that it will participate in the Stifel Healthcare Conference on November 19 in New York City and Jefferies London Healthcare Conference on November 21 (Press release, Kindred Healthcare, NOV 14, 2019, View Source [SID1234551324]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Richard Chin, Chief Executive Officer, will present and be available for one-on-one meetings. During this time, investors will have the opportunity to discuss recent developments, including the launch of KindredBio’s first product, study results from key therapeutic programs in development, and upcoming milestones.

Conference Details:

Stifel Healthcare Conference

Date: Tuesday, November 19, 2019

Presentation time: 10:20-10:50a.m. ET in Kennedy

Location: Lotte New York Palace Hotel

Webcast URL: Click here

Jefferies London Healthcare Conference

Date: Thursday, November 21, 2019

Location: Waldorf Hilton, London

An archived version of the above webcast will be available for 30 days on the KindredBio website.

On November 14, 2019 BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, reported that it will present at the Jefferies 2019 London Healthcare Conference on Thursday, November 21, 2019, at 6:20 a.m. ET (Press release, BD Pharmaceutical Systems, NOV 14, 2019, View Source [SID1234551323]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of BD’s presentations can be accessed from the BD corporate website at www.bd.com/investors and will be available for replay through Thursday, November 28, 2019.